- Home
- ACRV vs INBX Comparison
ACRV vs INBX Comparison
Compare ACRV & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- INBX
- Stock Information
- Founded
- ACRV 2018
- INBX 2010
- Country
- ACRV United States
- INBX United States
- Employees
- ACRV N/A
- INBX N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- INBX Health Care
- Exchange
- ACRV Nasdaq
- INBX Nasdaq
- Market Cap
- ACRV 59.9M
- INBX 168.1M
- IPO Year
- ACRV 2022
- INBX 2020
- Fundamental
- Price
- ACRV $1.18
- INBX $11.26
- Analyst Decision
- ACRV Strong Buy
- INBX Hold
- Analyst Count
- ACRV 5
- INBX 1
- Target Price
- ACRV $19.75
- INBX N/A
- AVG Volume (30 Days)
- ACRV 1.3M
- INBX 102.3K
- Earning Date
- ACRV 05-13-2025
- INBX 05-20-2025
- Dividend Yield
- ACRV N/A
- INBX 7.37%
- EPS Growth
- ACRV N/A
- INBX N/A
- EPS
- ACRV N/A
- INBX 112.62
- Revenue
- ACRV N/A
- INBX $200,000.00
- Revenue This Year
- ACRV N/A
- INBX N/A
- Revenue Next Year
- ACRV N/A
- INBX N/A
- P/E Ratio
- ACRV N/A
- INBX $0.10
- Revenue Growth
- ACRV N/A
- INBX N/A
- 52 Week Low
- ACRV $1.30
- INBX $10.80
- 52 Week High
- ACRV $10.29
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ACRV 29.23
- INBX 38.99
- Support Level
- ACRV $1.32
- INBX $11.73
- Resistance Level
- ACRV $1.50
- INBX $12.60
- Average True Range (ATR)
- ACRV 0.19
- INBX 0.84
- MACD
- ACRV 0.06
- INBX -0.00
- Stochastic Oscillator
- ACRV 2.08
- INBX 18.69
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.